ESTIMATING THE COST TO SOCIETY FOR EXENATIDE QW AND INSULIN GLARGINE IN THE UNITED STATES FOR THE TREATMENT OF TYPE 2 DIABETES

被引：0
|
作者：
Wang, B. C. [1 ]
Nguyen, H. [2 ]
Furnback, W. [3 ]
Guzauskas, G. F. [1 ]
Hurd, J. [4 ]
Garrison, L. P. [5 ]
机构：
[1] Elysia Grp Ltd, Taipei, Taiwan
[2] AstraZeneca, Ft Washington, PA USA
[3] Elysia Grp LLC, New York, NY USA
[4] AstraZeneca, Columbus, PA USA
[5] Univ Washington, Seattle, WA 98195 USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1288
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB26
引用
收藏
页码：A201 / A201
页数：1
相关论文
共 50 条
  • [31] Real-world characteristics of patients with type 2 diabetes initiating insulin glargine plus exenatide or insulin glargine plus liraglutide
    Di Genio, A.
    Ling, Z.
    Davis, K. L.
    Meyers, J. L.
    Dalal, M. R.
    DIABETOLOGIA, 2012, 55 : S328 - S328
  • [32] Efficacy and Safety of Exenatide QW vs. Placebo Added to Insulin Glargine in Uncontrolled Basal-Insulin Treated Type 2 Diabetes: DURATION-7 Trial
    Frias, Juan P.
    Rosenstock, Julio
    Somogyi, Aniko
    Jabbour, Serge A.
    Wang, Hui
    Hardy, Elise
    Guja, Cristian
    DIABETES, 2017, 66 : A34 - A35
  • [33] Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes
    Ray, Joshua A.
    Boye, Kristina S.
    Yurgin, Nicole
    Valentine, William J.
    Roze, Stephane
    McKendrick, Jan
    Tucker, Daniel M. D.
    Foos, Volker
    Palmer, Andrew J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (03) : 609 - 622
  • [34] COST-EFFECTIVENESS OF EXENATIDE VERSUS INSULIN GLARGINE FOR THE TREATMENT OF TYPE-2 DIABETES IN TURKEY: A LONG-TERM HEALTH ECONOMIC ANALYSIS
    Bruhn, D.
    Malhan, S.
    Kavuncubasi, S.
    Smith-Palmer, J.
    Reed, V
    VALUE IN HEALTH, 2009, 12 (07) : A406 - A406
  • [35] Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes
    Brodows, Robert G.
    Qu, Yongming
    Johns, Don
    Kim, Dennis
    Holcombe, John H.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (05) : 1395 - 1397
  • [36] Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes - A randomized trial
    Heine, RJ
    Van Gaal, LF
    Johns, D
    Mihm, MJ
    Widel, MH
    Brodows, RG
    ANNALS OF INTERNAL MEDICINE, 2005, 143 (08) : 559 - 569
  • [37] Effects of exenatide vs insulin glargine on cardiovascular risk factors in subjects with type 2 diabetes
    Horton, E. S.
    Cohen, A.
    Gibson, H.
    Lamparello, B.
    Herzlinger, S.
    McFarland, L.
    DIABETOLOGIA, 2009, 52 : S298 - S299
  • [38] Healthcare Expenditures Following Initiation of Insulin Glargine or Exenatide in Patients with-Type 2 Diabetes
    Herman, William H.
    Zhang, Quanwu
    Rosenstock, Julio
    DIABETES, 2009, 58 : A526 - A526
  • [39] Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes
    Liu, Lin
    Yan, Hongmei
    Xia, MingFeng
    Zhao, Lin
    Lv, Minzhi
    Zhao, Naiqin
    Rao, Shengxiang
    Yao, Xiuzhong
    Wu, Weiyun
    Pan, Baishen
    Bian, Hua
    Gao, Xin
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2020, 36 (05)
  • [40] THE IMPACT OF TREATMENT MODIFICATION ON HEALTHCARE EXPENDITURE IN PATIENTS WITH TYPE-2 DIABETES INITIATING EXENATIDE BID OR INSULIN GLARGINE
    Pawaskar, M.
    Bonafede, M.
    Johnson, B. H.
    Fowler, R.
    Hoogwerf, B. J.
    VALUE IN HEALTH, 2011, 14 (03) : A95 - A95
12345